This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Isaacs, S. N.
Right arrow Articles by Lambris, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isaacs, S. N.
Right arrow Articles by Lambris, J. D.

 Previous Article  |  Next Article 

Journal of Virology, August 2003, p. 8256-8262, Vol. 77, No. 15
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.15.8256-8262.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Restoration of Complement-Enhanced Neutralization of Vaccinia Virus Virions by Novel Monoclonal Antibodies Raised against the Vaccinia Virus Complement Control Protein

Stuart N. Isaacs,1 Emelia Argyropoulos,2 Georgia Sfyroera,2 Shamim Mohammad,1 and John D. Lambris2*

Department of Medicine, Division of Infectious Diseases,1 Protein Chemistry Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 191042

Received 14 March 2003/ Accepted 1 May 2003

The vaccinia virus complement control protein (VCP) is secreted by infected cells and has been shown to inhibit complement activation through interactions with C3b/C4b. It contains four short consensus repeat (SCR) domains. It has been suggested that all four SCRs are required for VCP's activity. To elucidate which SCR domains are involved in abolishing complement-enhanced neutralization of vaccinia virus virions, we generated and characterized a panel of mouse monoclonal antibodies (MAbs) raised against VCP. Ten MAbs were isolated and all recognized VCP on Western blots under reducing conditions as well as native-bound VCP in a sandwich enzyme-linked immunosorbent assay. Three of the 10 MAbs (2E5, 3D1, and 3F11) inhibited VCP's abolition of complement-enhanced neutralization of vaccinia virus virions. These MAbs blocked the interaction of VCP with C3b/C4b. The seven remaining MAbs did not alter VCP function in the complement neutralization assay and recognized VCP bound to C3b/C4b. To understand MAb specificity and mode of interaction with VCP, we mapped the MAb binding regions on VCP. The seven nonblocking MAbs all bound to the first SCR of VCP. One of the blocking MAbs recognized SCR 2 while the other two recognized either SCR 4 or the junction between SCRs 3 and 4, indicating that structural elements involved in the interaction of VCP with C3b/C4b are located within SCR domains 2 and 3 and 4. These anti-VCP MAbs may have clinical significance as therapeutic inhibitors of VCP's complement control activity and may also offer a novel approach to managing vaccinia virus vaccine complications that occur from smallpox vaccination.

* Corresponding author. Mailing address: Protein Chemistry Laboratory, Department of Pathology, University of Pennsylvania, 401C Stellar-Chance Building, Philadelphia, PA 19104-6100. Phone: (215) 746-5765. Fax: (215) 573-8738. E-mail: lambris{at}mail.med.upenn.edu.

Journal of Virology, August 2003, p. 8256-8262, Vol. 77, No. 15
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.15.8256-8262.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Adamo, J. E., Meseda, C. A., Weir, J. P., Merchlinsky, M. J. (2009). Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein. J. Gen. Virol. 90: 2604-2608 [Abstract] [Full Text]  
  • Liszewski, M. K., Leung, M. K., Hauhart, R., Fang, C. J., Bertram, P., Atkinson, J. P. (2009). Smallpox Inhibitor of Complement Enzymes (SPICE): Dissecting Functional Sites and Abrogating Activity. J. Immunol. 183: 3150-3159 [Abstract] [Full Text]  
  • Liszewski, M. K., Bertram, P., Leung, M. K., Hauhart, R., Zhang, L., Atkinson, J. P. (2008). Smallpox Inhibitor of Complement Enzymes (SPICE): Regulation of Complement Activation on Cells and Mechanism of Its Cellular Attachment. J. Immunol. 181: 4199-4207 [Abstract] [Full Text]  
  • Girgis, N. M., DeHaven, B. C., Fan, X., Viner, K. M., Shamim, M., Isaacs, S. N. (2008). Cell Surface Expression of the Vaccinia Virus Complement Control Protein Is Mediated by Interaction with the Viral A56 Protein and Protects Infected Cells from Complement Attack. J. Virol. 82: 4205-4214 [Abstract] [Full Text]  
  • Spiller, O. B., Mark, L., Blue, C. E., Proctor, D. G., Aitken, J. A., Blom, A. M., Blackbourn, D. J. (2006). Dissecting the Regions of Virion-Associated Kaposi's Sarcoma-Associated Herpesvirus Complement Control Protein Required for Complement Regulation and Cell Binding.. J. Virol. 80: 4068-4078 [Abstract] [Full Text]  
  • Likos, A. M., Sammons, S. A., Olson, V. A., Frace, A. M., Li, Y., Olsen-Rasmussen, M., Davidson, W., Galloway, R., Khristova, M. L., Reynolds, M. G., Zhao, H., Carroll, D. S., Curns, A., Formenty, P., Esposito, J. J., Regnery, R. L., Damon, I. K. (2005). A tale of two clades: monkeypox viruses. J. Gen. Virol. 86: 2661-2672 [Abstract] [Full Text]  
  • Mark, L., Lee, W. H., Spiller, O. B., Proctor, D., Blackbourn, D. J., Villoutreix, B. O., Blom, A. M. (2004). The Kaposi's Sarcoma-associated Herpesvirus Complement Control Protein Mimics Human Molecular Mechanisms for Inhibition of the Complement System. J. Biol. Chem. 279: 45093-45101 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»